---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-205099"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:22:19.768572+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Elegrobart Phase 3 REVEAL-2 meets primary endpoint; proptosis responder rate 50-54% vs 15% placebo (p<0.0001)

## Summary
- Proptosis responder rate at week 24: 50% (Q4W) and 54% (Q8W) vs 15% placebo; both p<0.0001.
- Diplopia responder rate 61% (Q4W) vs 38% placebo (p=0.0118); complete resolution 44% vs 25% (p=0.0295).
- Elegrobart well tolerated; 91% completed treatment, no treatment-related SAEs, low hearing impairment rates.
- BLA submission for elegrobart on track for Q1 2027; veligrotug PDUFA target action date June 30, 2026.
- Second positive Phase 3 trial for elegrobart; supports potential first subcutaneous autoinjector for TED.

## SEC filing metadata
- accession: 0001193125-26-205099
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312526205099/0001193125-26-205099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312526205099/d20977d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-205099
- JSON: https://secwatch.observer/filing/0001193125-26-205099.json
- Plain text: https://secwatch.observer/filing/0001193125-26-205099.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.